



52594-Review.docx

Quotes Excluded
Bibliography Excluded1%
SIMILAR

Name of Journal: *World Journal of Gastrointestinal Pathophysiology*

Manuscript NO: 52594

Manuscript Type: ORIGINAL ARTICLE

Observational Study

Outcomes of a drug shortage requiring switching in patients with ulcerative colitis

van Langenberg DR *et al.* Outcomes of a drug shortage in ulcerative colitis

Daniel R van Langenberg, Richard Kai-Yuan Cheng, Mayur Garg

Match Overview



1

Internet 23 words
crawled on 16-Nov-2019
www.shezbazed.com

1%

Outcomes of a drug shortage requiring switching in patients v



ALL

IMAGES

VIDEOS

121,000 Results

Any time ▼

Strategies for the Care of Adults Hospitalized for Active ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226798>

Ulcerative colitis is a chronic inflammatory disease of the colon; as many as 25% of **patients** with this disease **require** hospitalization. The goals of hospitalization are to assess disease severity, exclude infection, administer rapidly acting and highly effective medication regimens, and determine response.

Cited by: 56**Author:** Suresh Pola, Derek Patel, Sonia Ramam...**Publish Year:** 2012

Long-Term Outcome of Patients with Ulcerative Colitis and ...

<https://academic.oup.com/ecco-jcc/article/10/9/1015/2605261> ▼

Mar 28, 2016 · We studied the long-term **outcome of patients with ulcerative colitis** [UC] and primary non response [PNR] to infliximab and searched for predictors of **colectomy** in these **patients**. Methods: This retrospective, multi-centre study included UC patients from three European referral centres, with PNR to infliximab defined as a lack of clinical improvement after the **induction therapy**, leading to **drug discontinuation**.

Cited by: 26**Author:** Konstantinos Papamichael, Oliviane Riva...**Publish Year:** 2016

国内版 国际版



Outcomes of a drug shortage requiring switching in patients \



ALL

IMAGES

VIDEOS

121,000 Results

Any time ▾

Strategies for the Care of Adults Hospitalized for Active ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4226798>

Ulcerative colitis is a **chronic inflammatory disease** of the **colon**; as many as 25% of **patients** with this **disease require hospitalization**. The **goals of hospitalization** are to assess disease severity, exclude infection, administer rapidly acting and highly **effective medication regimens**, and ...

Cited by: 56

Author: Suresh Pola, Derek Patel, Sonia Ramam...

Publish Year: 2012

Long-Term Outcome of Patients with Ulcerative Colitis and ...

<https://academic.oup.com/ecco-jcc/article/10/9/1015/2605261> ▾

Mar 28, 2016 · We studied the long-term **outcome of patients with ulcerative colitis** [UC] and primary non response [PNR] to infliximab and searched for predictors of **colectomy** in these **patients**. Methods: This retrospective, multi-centre study included UC patients from three European referral centres, with PNR to infliximab defined as a lack of clinical improvement after the **induction therapy**, leading to **drug discontinuation**.

Cited by: 26

Author: Konstantinos Papamichael, Oliviane Riva...

Publish Year: 2016

[Adherence in ulcerative colitis: an overview](#)

Chat with Bing



You can chat with a live search engine, excited?

Say something...

Entyvio

Generic drug name: Vedolizumab

Vedolizumab is a monoclonal antibody developed by Millennium Pharmaceuticals, Inc for the treatment of ulcerative colitis and Crohn's disease. It binds to integrin $\alpha_4\beta_7$. Blocking the $\alpha_4\beta_7$ integrin results in gut-selective anti-inflammatory activity. It is marketed under the trade name Entyvio.

Precautions



[Side Effects](#)



[Interactions](#)



[Warnings](#)

Drug classes: Selective immunosuppressants

Pregnancy category: Consult a doctor